Breaking News Instant updates and real-time market news.

AAPL

Apple

$255.89

7.02 (2.82%)

, FIT

Fitbit

$7.12

0.94 (15.21%)

08:55
11/04/19
11/04
08:55
11/04/19
08:55

Notable open interest changes for November 4th

Friday's total option volume of 23.2 million contracts resulted in net open interest growth of 3.34 million calls and 3.33 million puts. Apple (AAPL), Fitbit (FIT), Uber (UBER) and Petrobras (PBR) saw the greatest growth. Top five new positions opened include 33k Sprint (S) Nov-19 6 puts, 27k Apple (AAPL) Jan-20 220 puts, 19k Fitbit (FIT) May-20 7 puts, 17k Apple (AAPL) Jan-20 215 puts and 15k Fitbit (FIT) 11/8 weekly 8 calls.

AAPL

Apple

$255.89

7.02 (2.82%)

FIT

Fitbit

$7.12

0.94 (15.21%)

UBER

Uber

$31.27

-0.18 (-0.57%)

PBR

Petrobras

$16.41

0.145 (0.89%)

  • 04

    Nov

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

AAPL Apple
$255.89

7.02 (2.82%)

11/01/19
DZBN
11/01/19
UPGRADE
Target $275
DZBN
Buy
Apple upgraded to Buy from Hold at DZ Bank
DZ Bank analyst Ingo Wermann upgraded Apple to Buy from Hold with a $275 price target.
10/31/19
LOOP
10/31/19
NO CHANGE
Target $250
LOOP
Hold
Apple price target raised to $250 from $200 at Loop Capital
Loop Capital analyst Ananda Baruah raised his price target on Apple to $250, saying its Q4 results and guidance were "solid". The analyst says the company delivered on its iPhone shipment units while its Services and Wearables businesses also performed "well ahead" of expectations. Baruah still keeps his Hold rating on Apple, noting that its current forward earnings multiple of 18.7-times is toward the high end of its 13- to 19-times multiple range over the past 2 years.
10/31/19
NEED
10/31/19
NO CHANGE
Target $280
NEED
Strong Buy
Apple price target raised to $280 from $250 at Needham
Needham analyst Laura Martin raised her price target on Apple to $280 and kept her Strong Buy rating after its better than expected Q4 results. The analyst is positive on the company's competitive position, its "marketing multiplier", and its "growing utility" with the focus on pay, card, and health businesses along with its new arcade, news, and TV services. Martin adds that bundling its offerings with combinations of family plans, along with free TV+ with new devices, will allow Apple to reduce its churn and boost the average revenue per user.
10/31/19
MSCO
10/31/19
NO CHANGE
Target $296
MSCO
Overweight
Apple price target raised to $296 at Morgan Stanley after 'clean' Q4 beat
Morgan Stanley analyst Katy Huberty raised her price target on Apple shares to $296 from $289 to reflect slightly higher revenue and stronger cash generation in FY20 following the company's Q4 results, which she called "clean across the board." The company's guidance reflects a positive start to the iPhone 11 cycle and she thinks strength across iPhone, Wearables, and Services are sustainable, Huberty added. She keeps an Overweight rating on Apple shares.
FIT Fitbit
$7.12

0.94 (15.21%)

11/04/19
SBSH
11/04/19
UPGRADE
Target $7.35
SBSH
Neutral
Fitbit upgraded to Neutral from Sell at Citi
Citi analyst Jim Suva upgraded Fitbit (FIT) to Neutral from Sell with a price target of $7.35, up from $2.00. The analyst cites the takeover by Alphabet (GOOGL) for the upgrade to Neutral as he believes the acquisition will likely occur. He does not see any antitrust hurdles nor additional bidders.
11/01/19
MSCO
11/01/19
UPGRADE
Target $7.35
MSCO
Equal Weight
Fitbit upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Katy Huberty upgraded Fitbit (FIT) to Equal Weight from Underweight with a price target of $7.35, up from $3.20, after the company agreed to be acquired by Google (GOOGL).
11/01/19
ROTH
11/01/19
DOWNGRADE
Target $7.35
ROTH
Neutral
Fitbit downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Searle downgraded Fitbit (FIT) to Neutral from Buy with a price target of $7.35, down from $8.00, after the company agreed to be acquired by Google (GOOGL). He sees the formal approval process and customary closing conditions "being ceremonial" and he does not expect an additional bidder. Searle also said he view Fitbit as a good fit for Google and thinks the monetization strategy for unique data in consumer and vertical healthcare markets will be "greatly accelerated" under the search giant's ownership.
11/04/19
DADA
11/04/19
DOWNGRADE
Target $7.35
DADA
Neutral
Fitbit downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Tom Forte downgraded Fitbit (FIT) to Neutral from Buy with a price target of $7.35, up from $5.75, after the company agreed to be acquired by Google (GOOGL). The analyst notes that while the deal may get some scrutiny from regulators, he is also encouraged that it is "finally" receiving "much deserved" attention for its healthcare-related business.
UBER Uber
$31.27

-0.18 (-0.57%)

10/25/19
NRCS
10/25/19
NO CHANGE
NRCS
Neutral
Northcoast checks show 'healthy' ride-hailing conditions during Q3
Northcoast analyst John Healy says his Q3 channel checks into ride-hailing conditions in the U.S. market indicate a backdrop that was "healthy at the margin with no meaningful slowdown." Further, Uber Technologies (UBER) seemed to win some of the "tug-of-war battle" between itself and Lyft (LYFT), as drivers seemed "marginally more pleased" with their time spent with Uber, Healy tells investors in a research note. He believes that at the margin, drivers during Q3 moved a bit more of their usage towards Uber. Meanwhile, Lyft continues to "inch pricing higher" for rides in many markets, while Uber is taking a more wait and see approach, says Healy. The analyst raised his Q3 earnings per share estimate for Lyft to (61c) from (72c), and lowered his Q3 estimate for Uber to (65c) from (63c). Healy keeps a Neutral rating on both stocks, but sees Lyft as the "cleaner/pure play story and at the margin more attractive."
10/31/19
GSCO
10/31/19
UPGRADE
Target $58
GSCO
Buy
Lyft upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry upgraded Lyft (LYFT) to Buy from Neutral with a price target of $58, down from $71. The stock in premarket trading is up 4%, or $1.92, to $46.03. The company reported better than expected Q3 revenue and management noted a trend toward higher prices across the industry, incremental engagement per rider, and a less promotional competitive environment, Terry tells investors in a research note. Lyft continues to gain share and is beginning to show the operational efficiencies, says the analyst, who believes the stock's risk/reward is favorable at current levels. Lyft competitor Uber Technologies (UBER) is trading up 15c to $33.90.
10/28/19
DBAB
10/28/19
NO CHANGE
Target $29
DBAB
Hold
Uber launch could drive adoption of Green Dot powered card, says Deutsche Bank
Deutsche Bank analyst Ashish Sabadra said the launch of Uber Money (UBER) could drive greater adoption of the Uber debit card, which is powered by Green Dot (GDOT). Since there are no monthly fees for the debit card account, Sabadra thinks the primary monetization will be through interchange and other fees. The analyst keeps a Hold rating on Green Dot shares with a $29 price target.
10/25/19
10/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Essa Pharma (EPIX) initiated with an Outperform at Oppenheimer. 2. Uber (UBER) initiated with a Buy at Guggenheim. 3. LogMeln (LOGM) assumed with a Sector Perform at RBC Capital. 4. MannKind (MNKD) initiated with an Overweight at Cantor Fitzgerald. 5. Sanderson Farms (SAFM) initiated with an Underperform at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PBR Petrobras
$16.41

0.145 (0.89%)

07/08/19
SBSH
07/08/19
NO CHANGE
Target $23
SBSH
Buy
Petrobras price target raised to $23 from $20.20 at Citi
Citi analyst Pedro Medeiros raised his price target Friday afternoon on Petrobras shares to $23 from $20.20 and kept a Buy rating on the shares. The analyst believes Petrobras can expand domestic oil production by ~25% in the second half of 2019. He forecasts the stock offers ~17.5% free cash flow to equity yield by 2020.
07/11/19
07/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Microsoft (MSFT) initiated with an Outperform at Cowen. 2. Petrobras (PBR) initiated with a Buy at Goldman Sachs. 3. Navidea (NAVB) initiated with a Buy at Maxim. 4. Immunic (IMUX) initiated with a Buy at Chardan. 5. Target (TGT) was initiated with a Conviction Buy at Goldman Sachs, while Walmart (WMT), Home Depot (HD), Lowe's (LOW), and Costco (COST) were initiated with a Buy, and Bed Bath & Beyond (BBBY) was initiated with a Sell. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/19
07/11/19
INITIATION
Target $21.6

Buy
Petrobras initiated with a Buy at Goldman Sachs
As previously reported, Goldman Sachs analyst Bruno Amorim started Petrobras with a Buy rating and a price target of $21.60, saying the company is in the process of transitioning from a "turnaround" story to one of growth and cash generation. The analyst adds that "after a decade" of disappointing on production growth forecasts, Petrobras is positioned to expand its production volume by about 9% per year in the 2018-2020 period. Amorim further believes that investors will respond well to the management's efforts in selling non-core assets to reduce leverage and invest the proceeds in the offshore Santos Basin.
07/11/19
GSCO
07/11/19
INITIATION
Target $19.7
GSCO
Buy
Petrobras initiated with a Buy at Goldman Sachs
Goldman Sachs started Petrobras with a Buy rating and $19.70 price target. The company's improving returns and free cash flow are not fully priced in at current share levels, Goldman says.

TODAY'S FREE FLY STORIES

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary  »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary  »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary  »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

17:58
12/08/19
12/08
17:58
12/08/19
17:58
Recommendations
Bluebird Bio, Johnson & Johnson, Amgen, Bristol-Myers, Regeneron analyst commentary  »

Piper says…

BLUE

Bluebird Bio

$79.51

-1.24 (-1.54%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

AMGN

Amgen

$233.74

0.3 (0.13%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

REGN

Regeneron

$372.26

4.02 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 21

    Jan

BGNE

BeiGene

$186.89

-2.3 (-1.22%)

17:50
12/08/19
12/08
17:50
12/08/19
17:50
Hot Stocks
BeiGene announces data from two clinical trials of Brukinsa at ASH meeting »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 27

    Feb

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

16:34
12/08/19
12/08
16:34
12/08/19
16:34
Hot Stocks
Eli Lilly presents interim clinical data from LOXO-305 dose escalation trial »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

16:32
12/08/19
12/08
16:32
12/08/19
16:32
Hot Stocks
Bristol-Myers announces data from multiple liso-cel studies at ASH meeting »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

QURE

uniQure

$66.06

1.5 (2.32%)

16:26
12/08/19
12/08
16:26
12/08/19
16:26
Hot Stocks
uniQure reports 1-year follow-up data from etranacogene dezaparvovec study »

uniQure announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FTSV

Forty Seven

$14.40

0.23 (1.62%)

15:56
12/08/19
12/08
15:56
12/08/19
15:56
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AQST

Aquestive Therapeutics

$8.02

-0.34 (-4.07%)

15:50
12/08/19
12/08
15:50
12/08/19
15:50
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

APRE

Aprea Therapeutics

$26.20

1.995 (8.24%)

15:23
12/08/19
12/08
15:23
12/08/19
15:23
Conference/Events
Aprea Therapeutics to hold a clinical update meeting »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

15:18
12/08/19
12/08
15:18
12/08/19
15:18
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

13:47
12/08/19
12/08
13:47
12/08/19
13:47
Periodicals
International Flavors in talks to buy DuPont nutrition unit, Bloomberg reports »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

KRYAY

Kerry Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWRF

China Tower

$0.00

(0.00%)

13:40
12/08/19
12/08
13:40
12/08/19
13:40
Upgrade
China Tower rating change at Deutsche Bank »

China Tower upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

13:37
12/08/19
12/08
13:37
12/08/19
13:37
Recommendations
Principia Biopharma analyst commentary at Stifel »

Principia shares have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.